Sarah E. Diver
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 1%
- Long-Term Effects of COVID-19
Papers in
- Physiology 26
- Asthma and respiratory diseases 26
-
- COVID-19 Clinical Research Studies 12
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Christopher Edward Brightling (18 shared papers)Gene Colice (4 shared papers)Claire L. Emson (4 shared papers)Ayman Megally (3 shared papers)Jane R. Parnes (3 shared papers)Latifa Khalfaoui (2 shared papers)Sally E. Wenzel (1 shared paper)RICHARD JOEL RUSSELL (3 shared papers)
- Journals
- The Lancet Respiratory Medicine (8 papers)The Lancet (6 papers)European Respiratory Journal (6 papers)Journal of Allergy and Clinical Immunology (4 papers)Allergy (3 papers)
- Partner nations
- United KingdomUnited StatesCanada
In The Last Decade
Sarah E. Diver
53 papers receiving 4.5k citations
Sarah E. Diver's Hit Papers
Peers
Comparison fields: 5 of 120
- Infectious Diseases 1.5k
- Neurology 844
- Physiology 1.3k
- Pulmonary and Respiratory Medicine 522
- Applied Microbiology and Biotechnology 37
Countries citing papers authored by Sarah E. Diver
This map shows the geographic impact of Sarah E. Diver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah E. Diver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah E. Diver more than expected).
Fields of papers citing papers by Sarah E. Diver
This network shows the impact of papers produced by Sarah E. Diver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah E. Diver. The network helps show where Sarah E. Diver may publish in the future.
Co-authors
The 25 scholars most cited alongside Sarah E. Diver, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study Hit paper breakdown → | 2021 | 504 |
| 2 | Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline Hit paper breakdown → | 2019 | 501 |
| 3 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 4 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 5 | Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Hit paper breakdown → | 2022 | 310 |
| 6 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 7 | Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial Hit paper breakdown → | 2021 | 268 |
| 8 | Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19 Hit paper breakdown → | 2022 | 252 |
| 9 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 10 | 2021 | 213 | |
| 11 | 2018 | 139 | |
| 12 | 2021 | 95 | |
| 13 | 2023 | 89 | |
| 14 | 2022 | 87 | |
| 15 | 2019 | 85 | |
| 16 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 17 | Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease Hit paper breakdown → | 2024 | 65 |
| 18 | 2021 | 51 | |
| 19 | Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials Hit paper breakdown → | 2025 | 48 |
| 20 | 2019 | 46 |
About Sarah E. Diver
Sarah E. Diver is a scholar working on Physiology, Infectious Diseases, Neurology, Pulmonary and Respiratory Medicine and Geriatrics and Gerontology, having authored 55 papers that have together received 4.6k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (26 papers), COVID-19 Clinical Research Studies (12 papers), Long-Term Effects of COVID-19 (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers), Lung Cancer Treatments and Mutations (2 papers), Lung Cancer Diagnosis and Treatment (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Health Services Management and Policy (1 paper). The work is most often cited by research in Infectious Diseases (1.5k citations), Neurology (844 citations), Physiology (1.3k citations), Pulmonary and Respiratory Medicine (522 citations) and Applied Microbiology and Biotechnology (37 citations). Sarah E. Diver has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Christopher Edward Brightling, Gene Colice, Claire L. Emson, Ayman Megally, Jane R. Parnes, Latifa Khalfaoui, Sally E. Wenzel, RICHARD JOEL RUSSELL, Andrew N Menzies-Gow and Michael E. Wechsler. Their work appears in journals such as The Lancet Respiratory Medicine, The Lancet, European Respiratory Journal, Journal of Allergy and Clinical Immunology and Allergy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.